FLT3 and acute myeloid leukemia: A cohort of 222 pretreatment AML samples from adult patients negative for known activating mutations in FLT3 (as well as KIT and NRAS) were sequenced for all coding exons and consensus splice junctions of FLT3. A total of 17 heterozygous nucleotide substitutions were identified.